An interventional study of Attentional Bias Modification in Depressive Disorder, sponsored by University of Oslo. Recruiting at 1 site in Norway. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-03-28.
Sponsored by University of Oslo · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Depressive Disorder with a site in Norway — 4 open to participants now, 5 under way, none of them phase 3. Depressive Disorder · Norway.
Among the 15 studies in Depressive Disorder with a site in Norway, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2022, is one of 7 with no phase, and was the 13th registered.
857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.
Browse Depressive Disorder studies →4 of the 15 studies in Depressive Disorder with a site in Norway are open now. Recruiting first, the newest first:
University Hospital of North Norway · Sites in Norway
Ages 22–65
Oslo University Hospital · Sites in Norway
Ages 13–18
Haukeland University Hospital · Sites in Norway
Ages 18+
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2022.
This study's planned enrollment of 246 is above the median of 87 across 691 interventional studies indexed under Depressive Disorder.
Median enrollment 52 across the 10 interventional studies, 200 across the 5 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 15 have an industry lead sponsor. The 10 most frequent:
University of Oslo is the lead sponsor of 177 studies on the registry; 24 are open to participants now.
University of Oslo has 1 study filed under Depressive Disorder — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Depressive Disorder with a site in Norway, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Background: Major depressive disorder (MDD) is a highly prevalent psychiatric condition associated with significant disability, mortality and economic burden. A large proportion of MDD patients are treated in primary health care (PHC) in the municipalities and represent a challenging group. Attentional Bias Modification (ABM) training in combination with antidepressants (SSRIs) could be an effective treatment. The overall aim of this study is to test the hypothesis that adding an ABM procedure to regular treatment with antidepressants in PHC will result in further improvement of symptoms compared to treatment with antidepressants alone (treatment as usual, TAU) and as compared to an active comparison condition.
Methods: A total of 246 patients with a diagnosis of MDD will be included in this study. The study is a three-armed pragmatic randomized controlled trial comparing the efficacy of ABM as add-on to treatment with antidepressants in primary care (ABM condition) compared to standard antidepressant treatment (TAU condition). In a third group participants will complete the same schedule of intermediate assessments as the ABM condition in addition to TAU , but no ABM, thus controlling for the non-training-specific aspects of the ABM condition (SSRI Active comparison group).
Discussion:
The clinical outcome of this study may help develop easy accessible, low cost treatment of depression in PHC. Moreover, the study aims to broaden our knowledge of optimal treatment for patients with a MDD by providing adjunct treatment to facilitate recovery and long term gain
Major Depressive Disorder (MDD) is a debilitating disorder that affects 15% of the population and is a leading cause of disability worldwide. The economic burden of MDD is enormous, with estimates of direct/indirect costs of $210.2 billion/year in the US alone.
Although both psychotherapy and antidepressant medications are effective, it is not uncommon for a patient with MDD to have temporary symptom reduction after treatment but require an extended amount of time for full restoration of function. A large proportion of MDD patients are treated in PHC in the municipalities and represent a challenging group to treat effectively. At the same time, it is known that early treatment and coordinated follow-up can be efficient even without costly specialist interventions or hospital treatment. Thus, improved treatment of MDD in municipalities represents a tremendous opportunity for improvement of public health and well being in the general population.
Considerable progress has been made in characterizing mechanisms underlying depression vulnerability and this may be harnessed to improve future treatment strategies. The ability to deal effectively with stress and life events is influenced by the ability of the brain to rapidly adapt, which in turn is a function of synaptic plasticity. Further, it has been hypothesized that the capacity of synapses for functional and structural change plays an important role in the pathophysiology and treatment of mood disorders. These dysfunctional neural mechanisms are affected by antidepressants and increased synaptic plasticity may be one of the therapeutic mechanisms. However, enhancing plasticity alone may not lead to a sufficient treatment response in all individuals affected by depression. Indeed, the entrenched attentional biases seen in depression, such as the tendency to focus on and recall negative information, may persist and be further entrenched by changes in the neural underpinnings of learning and memory. Furthermore, negative attention biases are associated with persistence of sad mood in major depressive disorder. However, selective biases in attention can potentially be modified by a simple computerized technique: The Attention Bias Modification Task (ABM).
While some studies have reported an effect of ABM in depression, definitive conclusions have been limited by small samples and poor trial methodology in many studies. However, recently a large RCT study showed that ABM training led to significantly greater decrease in clinician-rated symptoms of depression as compared to the control condition. ABM induced a change in AB towards relatively more positive stimuli for participants that also showed greater symptom reduction. A secondary network analysis indicated that ABM primarily influenced the symptom "interest" which could mediate both symptoms, social support, functioning and quality of life. Furthermore, a sub-sample was included in a brain imaging study revealing that the ABM active group showed reduced activation in the amygdala and the anterior cingulate cortex when passively viewing negative images compared to the sham group. Other studies have also found that experimentally modifying negatively biased attention reduces depressive symptoms. However, some studies have showed that ABM is not significantly better in improving depressive symptoms as compared to sham.
In addition to explore mechanisms of neuroplasticity, in parallel research there has also been interest in understanding the effects of antidepressant drugs on psychological processes involved in depression. Thus, a number of studies for more than a decade have documented that SSRIs modify biases in emotional processing, thus they work by modifying the same underlying basic mechanism that are the focus when applying ABM procedures. Emotional processing is influenced early in the treatment and independently of change in subjective mood, and these effects have been shown in depressed subjects as well as in healthy volunteers. Most of these studies investigated the effects of a single dose of an SSRI compared with placebo. However, it has been showed that antidepressants as prescribed in the community also increases processing for positive information.
A logical next step is to combine SSRIs as prescribed in primary health with an ABM procedure. Combining pharmacological and psychological regimes are gold standard treatment options in both depression and anxiety and is not associated with baseline severity.Treatments, such as cognitive behavioral therapy (CBT) might also change attentional biases, but by implementing an ABM procedure we will more readily target these biases directly. By combining ABM with today's treatment options, we could potentially increase treatment efficacy and shorten treatment duration. Furthermore, ABM has the advantage of being entirely deliverable on a digital platform without the need for therapist interaction.
The main aim of this study is to test the hypothesis that adding an ABM procedure to regular treatment with antidepressants in PHC will result in a clinically important improvement of symptoms compared to treatment with antidepressants alone (TAU), and as compared to an active comparison condition. Secondary aims are to investigate possible effects of the combined treatment on anxiety symptoms, emotional blunting, rumination, perceived stress, psychosocial functioning/work and suicidal risk. Thirdly, a number of potential moderators will also be investigated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The ABM intervention will be initiated two weeks after antidepressant treatment started (baseline) and continues with two daily sessions for two weeks.
Behavioral: Attentional Bias Modification
This group will in addition to TAU complete the schedule of intermediate assessments as in the ABM group, but no ABM , thus controlling for the aspects of the ABM group that are additional to TAU (increased engagement in cognitive activity and repeated assessment over time), but not including the training component itself (SSRI Active comparison group).
Behavioral: Attentional Bias Modification
Patients allocated to this group will be assessed at baseline and at the primary end-point as well after 12 weeks and 6 months follow-up. They will not complete any instruments during the intervention period to prevent the effect of some cognitive activity and provide a more ecologically valid version of TAU as it happens in primary care.
The ABM task is based on a computerized visual Dot-probe task. In the dot-probe task paired stimuli of negative (angry and fearful), positive (happy) or neutral faces are presented, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. In the ABM condition, probes are in the same locus as the more positive/less negative stimuli in 87% of the trials, as opposed to 13% with probes in the same locus as more negative/less positive stimuli. Thus, when completing the ABM, participants should learn to deploy their attention toward the relatively more positive stimuli, and in this way develop a more positive AB.
Also known as: ABM
Hamilton Depression Rating Scale
Clinician rated depressive symptoms. Range (0-50). Higher score indicate more depressive symptoms
Time frame: 8 weeks after baseline.
Beck Depression Inventory II
Self rated depressive symptoms. Range (0-63). Higher score indicate more depressive symptoms
Time frame: 8 weeks after baseline.
Beck Depression Inventory II
Self rated depressive symptoms, Range (0-63). Higher score indicate more depressive symptoms
Time frame: Follow-up 12 weeks after baseline.
Beck Depression Inventory II
Self rated depressive symptoms, Range (0-63). Higher score indicate more depressive symptoms
Time frame: Follow-up 6 months after baseline
Generalized Anxiety Disorder-7
Self rated anxiety symptoms. Range (0-21). Higher score indicate more anxiety symptoms
Time frame: 8 weeks after baseline.
Generalized Anxiety Disorder-7
Self rated anxiety symptoms. Range (0-21). Higher score indicate more anxiety symptoms
Time frame: 12 weeks after baseline.
Generalized Anxiety Disorder-7
Self rated anxiety symptoms. Range (0-21). Higher score indicate more anxiety symptoms
Time frame: 6 months after baseline
Oxford Depression Questionnaire
Self rated emotional blunting symptoms. Range (0-80). Higher score indicate more symptoms.
Time frame: 8 weeks after baseline
Oxford Depression Questionnaire
Self rated emotional blunting symptoms. Range (0-80). Higher score indicate more symptoms.
Time frame: 12 weeks after baseline.
Oxford Depression Questionnaire
Self rated emotional blunting symptoms. Range (0-80). Higher score indicate more symptoms.
Time frame: 6 months after baseline
Rumination Response Scale
Self rated level of rumination. Range (22-88). Higher score indicate more rumination.
Time frame: 8 weeks after baseline.
Rumination Response Scale
Self rated level of rumination. Range (22-88). Higher score indicate more rumination.
Time frame: 12 weeks after baseline
Rumination Response Scale
Self rated level of rumination. Range (22-88). Higher score indicate more rumination.
Time frame: 6 months after baseline
The Perceived Stress Scale
Self rated subjective level of stress. Range (0-40). Higher score indicate more perceived stress.
Time frame: 8 after baseline
The Perceived Stress Scale
Self rated subjective level of stress. Range (0-40). Higher score indicate more perceived stress.
Time frame: 12 weeks after baseline
The Perceived Stress Scale
Self rated subjective level of stress. Range (0-40). Higher score indicate more perceived stress.
Time frame: 6 months after baseline
The Work and Social Adjustment Scale
Self rated level of social functioning. Range (0-40). Higher score indicate poorer functioning
Time frame: 8 weeks after baseline.
The Work and Social Adjustment Scale
Self rated level of social functioning. Range (0-40). Higher score indicate poorer functioning
Time frame: 12 weeks after baseline.
The Work and Social Adjustment Scale
Self rated level of social functioning. Range (0-40). Higher score indicate poorer functioning
Time frame: 6 months after baseline.
Bergen Insomnia Scale
Self rated level of sleep problems. Range (0-42). Higher score indicate more insomnia
Time frame: 8 weeks after baseline.
Bergen Insomnia Scale
Self rated level of sleep problems. Range (0-42). Higher score indicate more insomnia
Time frame: 12 weeks after baseline.
Bergen Insomnia Scale
Self rated level of sleep problems. Range (0-42). Higher score indicate more insomnia
Time frame: 6 months after baseline.
Beck depression Inventory II (Suicid item)
Self reported level of suicidality. Range (0-3). Higher score indicate more suicidality.
Time frame: 8 weeks after baseline.
Beck depression Inventory II (Suicid item)
Self reported level of suicidality. Range (0-3). Higher score indicate more suicidality.
Time frame: 12 weeks after baseline.
Beck depression Inventory II (Suicid item)
Self reported level of suicidality. Range (0-3). Higher score indicate more suicidality.
Time frame: 6 months after baseline.
Dot probe
Degree of attentional bias- Measure mean reaction time.
Time frame: 8 weeks after baseline.
Dot probe
Degree of attentional bias- Measure mean reaction time.
Time frame: 12 weeks after baseline
Dot probe
Degree of attentional bias- Measure mean reaction time.
Time frame: 6 months after baseline.
Facial Expression Rating Task
Measure of detection threshold for correctly identifying the emotional facial expression. Measures of number of correct answer (Range 0-100%)
Time frame: 8 weeks after baseline
Facial Expression Rating Task
Measure of detection threshold for correctly identifying the emotional facial expression. Measures of number of correct answer (Range 0-100%)
Time frame: 12 weeks after baseline
Facial Expression Rating Task
Measure of detection threshold for correctly identifying the emotional facial expression. Measures of number of correct answer (Range 0-100%)
Time frame: 6 months after baseline
Plan to share: Undecided — Anonymized data may be shared on request
No publications or documents are linked to this record.
Started Sep 2022 (actual). Primary completion is estimated for Mar 2025, 30 months after the start.
Of 261 non-industry interventional studies with no phase under Depressive Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 30 months is close to that.
Counting every sponsor, half of 276 studies reached it within 29 months; a quarter within 15 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.